Northland Securities Weighs in on Alvotech FY2026 Earnings

Alvotech (NASDAQ:ALVO) – Analysts at Northland Securities issued their FY2026 earnings per share (EPS) estimates for Alvotech in a research note issued on Thursday, March 19th. Northland Securities analyst C. Byrnes forecasts that the company will earn ($0.08) per share for the year. The consensus estimate for Alvotech’s current full-year earnings is ($0.07) per share. Northland Securities also issued estimates for Alvotech’s FY2027 earnings at ($0.01) EPS.

Alvotech (NASDAQ:ALVO) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.50). Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%.The business had revenue of $173.20 million for the quarter, compared to the consensus estimate of $162.20 million.

A number of other brokerages also recently weighed in on ALVO. Weiss Ratings reissued a “sell (e+)” rating on shares of Alvotech in a report on Wednesday, January 21st. Zacks Research raised shares of Alvotech from a “strong sell” rating to a “hold” rating in a report on Thursday. Morgan Stanley set a $10.00 price objective on Alvotech in a report on Wednesday, December 3rd. Finally, Barclays assumed coverage on Alvotech in a research note on Monday, December 8th. They issued an “underweight” rating and a $5.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Alvotech currently has a consensus rating of “Hold” and an average target price of $8.60.

Alvotech Price Performance

Shares of NASDAQ:ALVO opened at $3.53 on Monday. Alvotech has a 1 year low of $3.42 and a 1 year high of $11.85. The company has a market capitalization of $1.06 billion, a PE ratio of 35.30 and a beta of 0.16. The business has a fifty day moving average price of $4.53 and a two-hundred day moving average price of $5.84.

Institutional Trading of Alvotech

Hedge funds and other institutional investors have recently modified their holdings of the business. State of Wyoming purchased a new stake in shares of Alvotech during the 3rd quarter valued at approximately $54,000. ProShare Advisors LLC grew its position in shares of Alvotech by 24.0% in the fourth quarter. ProShare Advisors LLC now owns 13,826 shares of the company’s stock valued at $71,000 after purchasing an additional 2,675 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Alvotech by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company’s stock worth $78,000 after purchasing an additional 3,110 shares in the last quarter. Magnetar Financial LLC purchased a new stake in Alvotech during the 3rd quarter worth about $86,000. Finally, Ulland Investment Advisors LLC bought a new position in Alvotech in the 3rd quarter worth about $92,000.

Trending Headlines about Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Q4 and FY‑2025 revenue beat and bullish 2026 outlook — Q4 revenue was $173M (+13% YoY) and FY revenue was $593M (+21% YoY); management reiterated 2026 revenue guidance of $650–700M and raised adjusted EBITDA guidance. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Positive Sentiment: Regulatory approvals, commercial launches and partner deals expand near‑term commercial runway — multiple biosimilars (e.g., AVT05, AVT03) cleared in Europe/UK, a marketing application accepted for AVT23, U.S. launch activity via partners (Selarsdi™), and supply/commercialization agreements with Sandoz for key territories. Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments
• Positive Sentiment: Balance sheet and leadership moves reduce execution risk — Alvotech raised ~\$300M, listed on Nasdaq Stockholm, expanded R&D via acquisitions, and appointed Lisa Graver as CEO and other senior hires to support scaling. Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO
• Neutral Sentiment: U.S. approvals expected late‑2026 but management says they will have minimal 2026 topline impact — this tempers upside from potential FDA wins this year. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage and price‑target dispersion — several buy/overweight ratings and median analyst target near \$9 show upside in some forecasts, but targets vary widely—expect mixed analyst reactions. Alvotech Reports Q4 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Short‑interest data reported for March appears inconsistent/invalid (entries show 0 shares and NaN increases), so short‑interest signals are currently unreliable. (Multiple short‑interest notices 3/18–3/20)
• Negative Sentiment: EPS missed consensus — reported EPS of $0.03 vs. consensus ~$0.13, which can pressure sentiment despite the revenue beat. Alvotech earnings summary
• Negative Sentiment: FDA inspection observations remain an overhang — management says improvements are underway and resubmissions are planned for Q2 2026, but regulatory risk could delay U.S. commercialization and investor confidence. Alvotech Q4 2025 and Full Year 2025 Financial Results

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).